Fosamax (alendronate) causes adverse GI effects more often than we originally thought

February 1999

New evidence suggests that Fosamax (alendronate) causes adverse GI effects more often than we originally thought.

A large Kaiser study shows that 1 in 3 women starting Fosamax report new GI symptoms...1 in 8 seek care for a GI disorder.

The risk is highest in women over age 70...those with a prior history of GI problems...or those also taking NSAIDs.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

drug reps to give out information about UNAPPROVED uses of their prescription drugs
Lovenox (enoxaparin) is the first low-molecular-weight heparin approved to TREAT deep vein thrombosis (DVT)
new drug for intermittent claudication
Monitoring plasma homocysteine levels is becoming more common
Gastroenterology new guidelines for treating H. pylori
Neurology & Pain new CNS stimulant called Provigil (modafinil)
Diabetes mix Humalog (insulin lispro) with long-acting insulins
Diabetes Glyset (miglitol), a new alpha-glucosidase inhibitor for type 2 diabetes
Diabetes Fenugreek supplements are now being promoted to diabetics
Women's Health more attention focused on urinary incontinence
Women's Health Fosamax (alendronate) causes adverse GI effects more often than we originally thought
Infectious Diseases new drug for HIV, Ziagen (abacavir)
Infectious Diseases minocycline is useful for mild to moderate scleroderma
Infectious Diseases Herp-Eeze, a new herbal supplement promoted for herpes
Multiple Sclerosis EARLIER treatment for patients with multiple sclerosis (MS)
Generics two significant new generics
Vaccines new pediatric immunization schedule
Vaccines revaccinate some patients with pneumococcal vaccine after five years
Practice chart of new drugs approved by the FDA in 1998